Researchers at Duke University have developed a promising therapeutic approach that addresses the root cause of chronic neuropathic pain: cellular energy depletion in damaged nerves. By extracting healthy mitochondria from laboratory-cultured cells and transplanting them directly into injured nerve tissues, the team achieved a 78% reduction in pain scores compared to 34% improvement with standard pain medications.
The breakthrough, published in Nature Neuroscience, offers new hope for approximately 25 million Americans suffering from neuropathic conditions including diabetic neuropathy, chemotherapy-induced nerve damage, and post-surgical pain syndromes. Traditional pain management approaches often prove inadequate for these debilitating conditions, leaving patients with limited therapeutic options. By targeting the fundamental energy crisis that drives nerve dysfunction, mitochondrial transplant therapy represents a paradigm shift in how clinicians approach chronic pain treatment.
Read the full article on GMJ Newsroom.
Was this article helpful?
